Payment overview · 2025
General Payments
$221.55
11 reported records · 7 companies
Healthcare provider profile · identity verified
Mukti Aich, MD
Allopathic & Osteopathic Physicians|Family Medicine · OCALA, FL · NPI 1609038082
Verified facts
What the public records show
CMS Open Payments records show Mukti Aich, MD received $221.55 in general payments during 2025 across 11 reported records.
Astellas Pharma US Inc accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.85 | 28.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.77 | 21.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.69 | 14.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.72 | 11.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.96 | 9.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.48 | 8.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.08 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.55 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.85 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 34 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 83 |
| Losartan Potassium | Losartan Potassium | 219 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 62 |
| Lisinopril | Lisinopril | 170 | 53 |
| Omeprazole | Omeprazole | 168 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 46 |
| Trazodone Hcl | Trazodone Hcl | 122 | 41 |
| Famotidine | Famotidine | 113 | 58 |
| Metformin Hcl | Metformin Hcl | 113 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 36 |
| Sertraline Hcl | Sertraline Hcl | 101 | 25 |
| Gabapentin | Gabapentin | 96 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 36 |
| Simvastatin | Simvastatin | 94 | 33 |
| Alprazolam | Alprazolam | 91 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 34 |
| Ozempic | Semaglutide | 87 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 28 |
| Furosemide | Furosemide | 77 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 59 |
| Metformin Hcl Er | Metformin Hcl | 74 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 18 |
| Potassium Chloride | Potassium Chloride | 71 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 28 |
| Mounjaro | Tirzepatide | 66 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 24 |
| Meloxicam | Meloxicam | 65 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 50 |
| Montelukast Sodium | Montelukast Sodium | 53 | 16 |
| Prednisone | Prednisone | 53 | 45 |
| Tramadol Hcl | Tramadol Hcl | 52 | 20 |
| Glimepiride | Glimepiride | 50 | 16 |
| Cephalexin | Cephalexin | 47 | 32 |
| Methylprednisolone | Methylprednisolone | 47 | 41 |
| Pregabalin | Pregabalin | 47 | 13 |
| Allopurinol | Allopurinol | 45 | 14 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Glipizide Er | Glipizide | 44 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 13 |
| Valsartan | Valsartan | 42 | 13 |
| Glipizide | Glipizide | 41 | 14 |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Buspirone Hcl | Buspirone Hcl | 36 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | 11 |
| Valacyclovir | Valacyclovir Hcl | 36 | 22 |
| Atenolol | Atenolol | 35 | 13 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 33 |
| Eliquis | Apixaban | 34 | 13 |
| Ramipril | Ramipril | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 30 |
| Mirtazapine | Mirtazapine | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | 11 |
| Carvedilol | Carvedilol | 27 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 22 | 13 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 14 |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Kesimpta Pen | Ofatumumab | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.55 · 11 records | Astellas Pharma US Inc | Cologuard Collection Kit, ELIQUIS, JARDIANCE, NURTEC ODT, Ozempic, UBRELVY, Veozah, WATCHMAN FLX, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error